Gastric cancer presents a significant global health challenge characterized by poor prognosis, exacerbated by delayed diagnosis and limited treatment efficacy. Recent advancements have integrated immunotherapy, advanced surgical techniques, nanoparticle therapies, biomarker- guided approaches, and targeted treatments to enhance personalized medicine strategies tailored to individual patient profiles. Conventional diagnostic modalities such as endoscopic ultrasound, multidetector computed tomography (MDCT), positron emission tomography (PET), and upper gastrointestinal endoscopy are pivotal for precise disease assessment and staging, complementing standard therapies like total gastrectomy and radiation. However, these methods have inherent limitations necessitating improvement. Technological innovations including laparoscopy, robotic- assisted surgery, precise radiotherapy guided by advanced imaging, and targeted therapies such as monoclonal antibodies and immune checkpoint inhibitors aim to mitigate procedural risks, optimize treatment accuracy, and expand therapeutic options. These advances aim to enable earlier detection, personalized treatment approaches, and enhanced clinical outcomes in managing gastric cancer, with ongoing developments focusing on refining therapies and increasing global access to advanced healthcare solutions.